# Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

> **NCT05195632** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pierre Fabre Medicament** · enrollment: 63 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Encorafenib
- **DRUG:** Binimetinib

## Key facts

- **NCT ID:** NCT05195632
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-02
- **Primary completion:** 2024-05-27
- **Final completion:** 2026-12-14
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05195632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05195632, "Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05195632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*